Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study

June 12, 2026 10:52 AM EDT News Briefing En­liv­en prices $400M of­fer­ing; Jazz drug Zepzel­ca fails con­fir­ma­to­ry study ENDPOINTS Plus news about Cari­bou, Adi­al, and the Beneluxa Ini­tia­tive. 💵 En­liv­en Ther­a­peu­tics’ da­ta and raise: The Burlingame, CA-based biotech priced a Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER